According to previous retrospective studies, irAEs induced by nivolumab or pembrolizumab—both monoclonal antibodies that target programmed cell death protein 1 (PD-1)—are associated with survival benefit in patients with advanced NSCLC and malignant melanoma 10-18. The gene discussed is PDCD1; the disease is melanoma.